Five hundred seventy CD-1 mice were divided equally by gender and assi
gned to three groups of 70 per gender and one group of 75 per gender.
The first three groups were dosed via oral intubation at 0, 0.5, and 2
.0 mg/kg/day while the larger groups were dosed at 4.5 mg/kg/day. Obse
rvations were made twice daily and blood smears taken at 12 and 18 mon
ths. All animals were sacrificed at 18 months; organs were weighed and
examined grossly and microscopically. Treated animals showed decrease
d body weight gain and male mice demonstrated increased mortality, par
ticularly at the high-dose level. Gross and microscopic lesions were n
ot obviously dose dependent. In this study, acrolein was not shown to
have oncogenic properties.